MentionFox
Home › funding signals › Ikena Oncology, Inc.
Form D · on the record

Ikena Oncology — Form D filing, July 2025

Ikena Oncology, Inc. filed a Form D with the Securities and Exchange Commission on 2025-07-18.

Ikena Oncology, Inc. filed a Form D notice of an exempt securities offering with the SEC on July 18, 2025. Its industry group is Biotechnology. It names Mark Manfredi (Executive Officer, Director), Jotin Marango (Executive Officer), Jeffrey Ecsedy (Executive Officer) (SEC Form D, July 18, 2025).

125 companies raised this week.

Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.

Andersen Aggregator LLC$1.9BBusiness services
AT Umbrella LLC$1.9BBusiness services
Legora, Inc.$221MAI and software
MD INVESTMENT LLC$169MBusiness services
Serval Inc.$149MAI and software
Check one company free

Jean-Francois Formela is also named on 1 other Form D filing ↓

Is this your company?

Key facts

Run the free check on Ikena Oncology, Inc. →

Sell to companies like Ikena Oncology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Ikena Oncology, Inc.

New Form D on file · 2025-07-18 · the record

$0
raise on the record
D
filing
0
investors in
MASSACHUSETTS
based
Open the record →

What the record says

FilingForm D
Filed2025-07-18
Industry groupBiotechnology
Entity typeCorporation
Incorporated inDELAWARE
BasedBOSTON, MASSACHUSETTS
CIK1835579
Accession0001470831-25-000095

Pitching, partnering or investing alongside them? See who really runs and owns Ikena Oncology, Inc.

Free to see. No signup.

Keep reading

More on the people and the money behind Ikena Oncology, Inc., from the filings we hold.

The people on this filing

Raised through the same sales agent

LEERINK PARTNERS LLC received sales compensation on this raise and on 15 other raises we hold, nearest in date first:

More raises like this

Biotechnology raises by companies based in Massachusetts, filed in July 2025, largest first.

What do you want to do with Ikena Oncology, Inc.?

Get the full cited report on Ikena Oncology, Inc.

What the filing shows about Ikena Oncology, Inc.

  • The filing names 10 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Ikena Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

Who the filing names, and in what role

The filing gives Ikena Oncology, Inc.'s address as 645 Summer Street, Suite 101, Boston, MA 02210.

What the filing says

  • Offered: $75,000,000. Sold: nothing yet. Left to sell: $75,000,000. (filing)
  • Investors: 0 had already invested. (filing)
  • Date of first sale: yet to occur. (filing)
  • Types of securities: Equity. (filing)
  • Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. (filing)
  • On the business combination question: the filing adds “Concurrent private placement financing in connection with the Agreement and Plan of Merger made by and among the Issuer, Inmagene Biopharmaceuticals and certain other parties thereto, as described in the Form 8-K filed by the Issuer on December 23, 2024.” (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Ikena Oncology, Inc. See pricing

Is Ikena Oncology, Inc. a real, registered company?

Ikena Oncology, Inc. is a registered filer with the SEC (CIK 1835579) and has filed since 2023-08-18. 2 filings are on record, the latest on 2025-07-18.

A filing shows the company exists and what it reports about itself. It is not an audit or a rating.

Who runs Ikena Oncology, Inc.?

Ikena Oncology, Inc.'s Form D of 2025-07-18 names Mark Manfredi, Jotin Marango, Jeffrey Ecsedy and 7 more as its officers, directors or promoters.

How much has Ikena Oncology, Inc. raised?

Its new offerings report $42.57M sold across 1 offering, as its own filings state.

Filing history · 2 filings on this registrant
Form D · 2023-08-18 · $42.57MForm D · 2025-07-18 · this page 2023-08-18 2025-07-18

Each marker is one filing. The larger marker is the filing this page is about.

Biotechnology · by week

Trailing twelve months. 769 filings in Biotechnology, totalled by week.

Want the whole picture on Ikena Oncology, Inc.?

What the filing shows about Ikena Oncology, Inc.

  • The filing names 10 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Ikena Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Ikena Oncology, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind Ikena Oncology, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.

Sourced from the filing index on sec.gov.

RSS

Tools for this story

Each opens in a new tab, filled in for Ikena Oncology, Inc.. With no account yet, you sign up free and land on the result.

Cite this page

Permanent URL: https://mentionfox.com/funding/ikena-oncology-inc-form-d-25000001
Last updated 2026-11-01
Primary record: SEC filing 1 · SEC filing 2
Ikena Oncology — SEC Form D filing, July 2025. MentionFox, 2026-11-01. https://mentionfox.com/funding/ikena-oncology-inc-form-d-25000001